Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066333 · ClinicalTrials.gov registry record · Phase 2
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
A Phase 2 study of Adrenocortical Carcinoma and ACC, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT06066333: Recruiting Phase 2 study of Adrenocortical Carcinoma and ACC, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06066333 is a Phase 2 study of Adrenocortical Carcinoma and ACC that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 362-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06066333, a Phase 2 study of Adrenocortical Carcinoma and ACC, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Primary Outcome
The primary objective of this pilot study is to evaluate the safety of treatment with ablative Radiotherapy/RT followed by pembrolizumab in patients with advanced Adrenocortical Carcinoma/ACC by evaluating treatment related adverse events. AEs will be recorded according to "Common Terminology Criteria for Adverse Events" v5.0 (CTCAE).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Ablative Radiotherapy
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2026-09-27 |
| Phase | Phase 2 |
What NCT06066333 shows while recruiting
NCT06066333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 362-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06066333 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06066333 about?
NCT06066333 is a clinical study titled "Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma". The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
What is the current status of trial NCT06066333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-09-27. Estimated completion is 2026-09-27.
What conditions does trial NCT06066333 study?
This clinical trial studies the following conditions: Adrenocortical Carcinoma, ACC, Metastatic Adrenocortical Carcinoma.
What interventions are being tested in trial NCT06066333?
The interventions under investigation include: Pembrolizumab (DRUG), Ablative Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT06066333?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066333 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenocortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06066333's enrollment target sits among peer trials
12 9th of 8 the lowest of 8 other Adrenocortical Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adrenocortical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
-
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
ACTIVE NOT RECRUITING
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI